Biotech's Innovation Paradox: Breakthroughs Stalled by Systemic Costs

Resources

Resources & Recommendations

Books

• "Where Are All the Trillion Dollar Biotechs" by Lada Nuzum - This post discusses the economic challenges and contradictions within the biotechnology industry.
• "The Structure Between China and the United States" by Dan Wang - This book is referenced for its analysis of the relationship between China and the US, particularly in the context of technological and industrial states.

Articles & Papers

• "The Biotech Paradox: Why the Business of Biotech is Collapsing While the Technology is Exploding" (Implied by episode discussion and guest's background) - This topic underpins the entire episode, discussing the disconnect between scientific advancement and economic struggles in biotech.

People Mentioned

• George Yancopoulos (Co-founder of Regeneron) - Mentioned as a figure from biotech's early days, highlighting the historical cost of patient trials.
• Dan Wang (China Analyst) - Quoted for his characterization of China as an "engineering state" and America as a "lawyer state" in the context of innovation.
• Benjamin Franklin - Referenced as a founding father representing America's innovative spirit.
• Leonard Shaffer (Co-founder of Regeneron) - Mentioned alongside George Yancopoulos as scientists defining the future of biotech.
• Michael Fishbach (Stanford Scientist) - Discussed for his work on new modalities in biology and potential mechanisms for aging.
• Irvin Weissman (Stanford Professor) - Cited as an example of a scientist whose new cancer targeting mechanism was quickly followed by Chinese biotech.
• Carl June (Early Developer of CAR-T therapy) - Mentioned for his questioning of why investigator-initiated trials for cell and gene therapy are not more prevalent in the US.
• Brian Johnson - Referenced for his "Blueprint" or "Don't Die" protocol related to personal health and longevity.

Organizations & Institutions

• Regeneron - Mentioned as an early biotech company to highlight the historical cost of patient trials.
• Amplify - The venture capital firm where Elliot Hershberg is a partner, focusing on platform companies.
• FDA (Food and Drug Administration) - Discussed extensively regarding its role in drug development, regulation, and the potential for modernization.
• Genentech - Used as a historical benchmark for early biotech success.
• Amgen - Mentioned alongside Genentech as an example of early biotech success.
• Human Genome Project - Referenced as a scientific endeavor that promised precision medicine.
• CFDA (China Food and Drug Administration) - Discussed in the context of China's regulatory processes for drug development.
• Moderna - Mentioned for its cancer vaccines, highlighting platform-based product development.
• BioNTech - Mentioned alongside Moderna for its cancer vaccines.
• Eli Lilly (Lily) - Discussed for its development of GLP-1 drugs, including semaglutide for Alzheimer's trials.
• Novo Nordisk - Mentioned as a key player in the development of GLP-1 drugs.
• Pfizer - Referenced for terminating its GLP-1 program due to perceived patient reluctance for chronic injectables.
• Merck - Mentioned as an early pharmaceutical company that established vertically integrated research labs.
• Novartis - Mentioned in the context of the development of Cosentyx, a TNF alpha antibody.
• AbbVie - Mentioned in the context of Humira, a successful TNF alpha antibody.
• Gilead Sciences - Mentioned in the context of Veklury (Remdesivir), a drug used for COVID-19.
• Stanford University - Referenced as a source of scientific talent and innovation.
• Medicare - Discussed as a primary payer for age-related diseases and its implications for incentivizing preventative care.

Courses & Educational Resources

• a16z Podcast (YouTube, Apple Podcasts, Spotify, X @a16z, Substack a16zsubstack.com) - The podcast itself, with various platforms for further engagement.

Websites & Online Resources

• a16z.com/disclosures - Provided for more details on investments and disclosures related to the podcast content.

Other Resources

• GLP-1 drugs (e.g., Semaglutide, Rybelsus) - Discussed as a significant drug class with broad societal impact, potentially bending the curve on aging and chronic diseases.
• CAR-T therapy - Mentioned as a type of cell and gene therapy.
• CRISPR - Discussed as a gene-editing technology and its potential applications.
• Recombinant DNA Technology - Highlighted as a foundational technology in biotech.
• mRNA Vaccines - Cited as a transformative technology for vaccine development.
• Monoclonal Antibodies - Discussed as a key therapeutic modality, particularly in cancer treatment.
• Small Molecules - Referenced as a traditional therapeutic modality.
• Epigenetic Editors - Mentioned as a potential future therapeutic modality for aging.
• Gene Editors - Mentioned as a potential future therapeutic modality for aging.
• Gene Therapies - Discussed as a potential future therapeutic modality for aging.
• TNF alpha antibodies (e.g., Humira, Cosentyx) - Discussed as a class of drugs where being first to market wasn't the sole determinant of success.
• PCKSK9 inhibitors - Mentioned as a class of drugs that could be included in an "aging stack."
• SRNAs (Small interfering RNAs) - Mentioned as a potential preventative medicine.
• Orphan Drug Act - Discussed for its role in incentivizing the development of drugs for rare diseases and the proposal for a similar incentive for common/age-related diseases.
• Investigator-Initiated Trials (IITs) - Discussed in the context of regulatory processes in the US, China, Australia, and New Zealand.
• Virtual Cells - Mentioned as a potential future application of AI in drug development.
• In silico toxicity studies - Discussed as an area where AI is currently being applied in preclinical drug development.
• Next-generation sequencing - Mentioned in the context of platform-based cancer vaccines.
• RNA cancer vaccines - Discussed as a personalized therapeutic approach.
• Sarcopenia - Discussed as a condition related to muscle loss in the elderly, with potential for drug development.
• Caloric Restriction - Mentioned as a method to extend lifespan, with discussion on its effectiveness and application to human diets.
• Lipitor - Cited as an example of a blockbuster drug from the "lipidator era."